Trials / Unknown
UnknownNCT04924179
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
A Phase II, Single-arm, Open-label, Single Center Study of Tislelizumab Combined With Fruquintinib and SBRT as A Third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab plus Fruquintinib and SBRT | Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days. |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2022-12-01
- Completion
- 2024-06-01
- First posted
- 2021-06-11
- Last updated
- 2022-08-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04924179. Inclusion in this directory is not an endorsement.